Pediatrix Medical (MD) EBITDA (2009 - 2026)

Pediatrix Medical has disclosed EBITDA across 18 years of filings, most recently posting $29.0 million for Q1 2026.

• In Q1 2026, EBITDA rose 34.96% year-over-year to $29.0 million; the TTM figure through Mar 2026 stood at $174.6 million (up 316.87% YoY), while the FY2025 annual figure was $167.1 million, up 270.61% from the prior year.
• EBITDA eased to $29.0 million in Q1 2026, from $33.8 million in the prior quarter.
• Over the last five years, EBITDA for MD reached as high as $72.0 million in Q3 2025 and fell as low as -$152.8 million in Q2 2024.
• The 5-year median for EBITDA is $25.9 million (2022), against an average of $5.9 million.
• Annual changes were most pronounced in 2024 — EBITDA tumbled 647.86% — and 2025, when it soared 425.42%.
• A 5-year view of EBITDA shows it stood at $30.0 million in 2022, then sank by 509.61% to -$123.0 million in 2023, then jumped by 124.08% to $29.6 million in 2024, then gained by 14.28% to $33.8 million in 2025, then fell by 14.21% to $29.0 million in 2026.
• According to Business Quant data, EBITDA over the past three periods registered $29.0 million, $33.8 million, and $72.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.